Literature DB >> 15956581

Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion.

Marco Patrone1, Massimiliano Secchi, Loretta Fiorina, Mariagrazia Ierardi, Gabriele Milanesi, Andrea Gallina.   

Abstract

Human cytomegalovirus (HCMV) growth in endothelial cells (EC) requires the expression of the UL131A-128 locus proteins. In this study, the UL130 protein (pUL130), the product of the largest gene of the locus, is shown to be a luminal glycoprotein that is inefficiently secreted from infected cells but is incorporated into the virion envelope as a Golgi-matured form. To investigate the mechanism of the UL130-mediated promotion of viral growth in EC, we performed a complementation analysis of a UL130 mutant strain. To provide UL130 in trans to viral infections, we constructed human embryonic lung fibroblast (HELF) and human umbilical vein endothelial cell (HUVEC) derivative cell lines that express UL130 via a retroviral vector. When the UL130-negative virus was grown in UL130-complementing HELF, the infectivity of progeny virions for HUVEC was restored to the wild-type level. In contrast, the infectivity of the UL130-negative virus for UL130-complementing HUVEC was low and similar to that of the same virus infecting control noncomplementing HUVEC. The UL130-negative virus, regardless of whether or not it had been complemented in the prior cycle, could form plaques only on UL130-complementing HUVEC, not control HUVEC. Because (i) both wild-type and UL130-transcomplemented virions maintained their infectivity for HUVEC after purification, (ii) UL130 failed to complement in trans the UL130-negative virus when it was synthesized in a cell separate from the one that produced the virions, and (iii) pUL130 is a virion protein, models are favored in which pUL130 acquisition in the producer cell renders HCMV virions competent for a subsequent infection of EC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956581      PMCID: PMC1143720          DOI: 10.1128/JVI.79.13.8361-8373.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Driving cells into atherosclerotic lesions--a deleterious role for viral chemokine receptors?

Authors:  H Hengel; C Weber
Journal:  Trends Microbiol       Date:  2000-07       Impact factor: 17.079

2.  Coding potential of laboratory and clinical strains of human cytomegalovirus.

Authors:  Eain Murphy; Dong Yu; Jane Grimwood; Jeremy Schmutz; Mark Dickson; Michael A Jarvis; Gabriele Hahn; Jay A Nelson; Richard M Myers; Thomas E Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

3.  Genetic content of wild-type human cytomegalovirus.

Authors:  Aidan Dolan; Charles Cunningham; Ralph D Hector; Aycan F Hassan-Walker; Lydia Lee; Clare Addison; Derrick J Dargan; Duncan J McGeoch; Derek Gatherer; Vincent C Emery; Paul D Griffiths; Christian Sinzger; Brian P McSharry; Gavin W G Wilkinson; Andrew J Davison
Journal:  J Gen Virol       Date:  2004-05       Impact factor: 3.891

4.  Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events.

Authors:  G Gerna; E Percivalle; F Baldanti; S Sozzani; P Lanzarini; E Genini; D Lilleri; M G Revello
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome.

Authors:  C Sinzger; K Schmidt; J Knapp; M Kahl; R Beck; J Waldman; H Hebart; H Einsele; G Jahn
Journal:  J Gen Virol       Date:  1999-11       Impact factor: 3.891

6.  Retroviral vector targeting to human immunodeficiency virus type 1-infected cells by receptor pseudotyping.

Authors:  N V Somia; H Miyoshi; M J Schmitt; I M Verma
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis.

Authors:  Caterina Bason; Roberto Corrocher; Claudio Lunardi; Patrizia Puccetti; Oliviero Olivieri; Domenico Girelli; Riccardo Navone; Ruggero Beri; Enrico Millo; Alberto Margonato; Nicola Martinelli; Antonio Puccetti
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

8.  Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis.

Authors:  Michael Weis; Thomas N Kledal; Ken Y Lin; Shyam N Panchal; S Z Gao; Hannah A Valantine; Edward S Mocarski; John P Cooke
Journal:  Circulation       Date:  2004-01-19       Impact factor: 29.690

9.  Human cytomegalovirus interleukin-10 downregulates metalloproteinase activity and impairs endothelial cell migration and placental cytotrophoblast invasiveness in vitro.

Authors:  Takako Yamamoto-Tabata; Susan McDonagh; Hsin-Ti Chang; Susan Fisher; Lenore Pereira
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  HIV-1 Nef enhances both membrane expression and virion incorporation of Env products. A model for the Nef-dependent increase of HIV-1 infectivity.

Authors:  Ilaria Schiavoni; Susanna Trapp; Anna Claudia Santarcangelo; Valentina Piacentini; Katherina Pugliese; Andreas Baur; Maurizio Federico
Journal:  J Biol Chem       Date:  2004-03-19       Impact factor: 5.157

View more
  50 in total

1.  A viral regulator of glycoprotein complexes contributes to human cytomegalovirus cell tropism.

Authors:  Gang Li; Christopher C Nguyen; Brent J Ryckman; William J Britt; Jeremy P Kamil
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

Review 2.  Human cytomegalovirus tropism for endothelial cells: not all endothelial cells are created equal.

Authors:  Michael A Jarvis; Jay A Nelson
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

3.  Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion.

Authors:  Brent J Ryckman; Michael A Jarvis; Derek D Drummond; Jay A Nelson; David C Johnson
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Natural antisense transcripts of UL123 packaged in human cytomegalovirus virions.

Authors:  Cui-Qing Yang; Ling-Feng Miao; Xing Pan; Cong-Cong Wu; Simon Rayner; Edward S Mocarski; Han-Qing Ye; Min-Hua Luo
Journal:  Arch Virol       Date:  2013-07-25       Impact factor: 2.574

5.  Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells.

Authors:  Frances M Saccoccio; Anne L Sauer; Xiaohong Cui; Amy E Armstrong; El-Sayed E Habib; David C Johnson; Brent J Ryckman; Aloysius J Klingelhutz; Stuart P Adler; Michael A McVoy
Journal:  Vaccine       Date:  2011-02-22       Impact factor: 3.641

6.  Neutralizing activity of saliva against cytomegalovirus.

Authors:  Frances M Saccoccio; Mary K Gallagher; Stuart P Adler; Michael A McVoy
Journal:  Clin Vaccine Immunol       Date:  2011-07-27

Review 7.  Cytomegalovirus antivirals and development of improved animal models.

Authors:  Alistair McGregor; K Yeon Choi
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-09-01       Impact factor: 4.481

8.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

9.  Human cytomegalovirus and human immunodeficiency virus type-1 co-infection in human cervical tissue.

Authors:  Andrea M Fox-Canale; Thomas J Hope; Jeffrey Martinson; John R Lurain; Alfred W Rademaker; James W Bremer; Alan Landay; Gregory T Spear; Nell S Lurain
Journal:  Virology       Date:  2007-08-22       Impact factor: 3.616

10.  Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.

Authors:  Annalisa Macagno; Nadia L Bernasconi; Fabrizia Vanzetta; Erica Dander; Antonella Sarasini; Maria Grazia Revello; Giuseppe Gerna; Federica Sallusto; Antonio Lanzavecchia
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.